

MANAGEMENT OF PSYCHOSIS IN PRIMARY CARE

LYDIA CHWASTIAK MD, MPH
PROFESSOR, UW DEPARTMENT OF PSYCHIATRY AND
BEHAVIORAL SCIENCES
SEPTEMBER 21, 2023







SPEAKER DISCLOSURES

None

Planner disclosures

The following series planners have no relevant conflicts of interest to disclose; other disclosures have been mitigated.

Mark Duncan MD

Rick Ries MD

Kari Stephens PhD

Barb McCann PhD

Anna Ratzliff MD PhD

Betsy Payn MA PMP

Esther Solano

Cara Towle MSN RN




OBJECTIVES

By the end of this session, participants will

- 1. Understand how to assess a person with possible psychosis, including consideration of underlying or concurrent conditions
- 2. Know the recommended first-line medications for treatment of psychosis
- 3. Identify two changes they can make in current practice to mitigate risks among their patients who are treated with antipsychotic medications



WHAT IS PSYCHOSIS?



http://www.psychosis101.ca

- Psychosis refers to a condition of the mind involving a "loss of contact with reality."
- People experiencing psychosis may exhibit some personality changes and thought disorder (hallucinations, delusions, odd speech).
- May be accompanied by unusual or bizarre behavior, as well as difficulty with social interaction and impairment in daily life activities.
- Occurs in 3/100 people at some point in their lifetime



EARLY IDENTIFICATION IS KEY

- Approximately 100,000 youth and young adults experience an episode of psychosis each year—or 274 young people each day.
- 3X as many young people who have experienced psychosis will drop out of school compared to their peers.
- Treatment works. 77% of those experiencing first episode psychosis will have a remission of symptoms with medication
- The average duration of untreated psychosis in the US is more than 2 years.





WHO IS TREATING PSYCHOSIS?



- 1.6% of US adults received prescription for antipsychotic medication in 2013-2018;¹
- 3.1 million people; \$18 B
- More than 30% were by nonpsychiatric prescribers²



¹Dennis JA, BMC Psychiatry 2020; 20:483;

²Olfson M et al, J Clin Psychiatry. 2015; Oct;76(10):1346-53

How much has antipsychotic use increased?



Source: 1. IMS Institute for Healthcare Informatics. Report to Neurocrine Biosciences, Inc. 1992-2014.

©2017 Neurocrine Biosciences, Inc. All Rights Reserved. CP-TD-US-0114 04/17



ASSESSMENT OF PSYCHOSIS

- 1. Identify symptoms of psychosis: history and mental status exam
- 2. Rule out substance use or medical cause (e.g., alcohol or delirium due to acute medical conditions) that require treatment
- 3. Ask about previous episodes and treatment and family history





PSYCHOSIS: KNOW THE SIGNS

| F | Functioning | Functional decline |
|---|-------------|---|
| A | Atypical | Atypical perceptual experiences |
| C | Cognition | Cognitive difficulties |
| Т | Thoughts | Thought disturbance or unusual beliefs |
| S | Speech | Speech or behavior that is disorganized |



HOW TO ASK....

| Symptoms | Person | Family |
|----------------|--|--|
| Hallucinations | e.g. Do you hear voices or see things that no one else can? | e.g. Do you see the person talking to someone else when alone? As if the person is talking to someone? |
| Delusions | e.g. Do you believe that someone is planning to hurt you? Do you feel that you are under surveillance? | e.g. Did the person share any ideas that you found strange and unlikely to be true? |

Remember the Mental Status Exam: appearance and speech



ALWAYS ASSESS SUICIDE RISK

- 20-40% of people with psychosis will attempt suicide in their lifetime and 8-10% will die by suicide
- You must always assess patients with psychosis for suicide.
- Imminent risk:
 - Current thoughts and/or plan to commit suicide or self-harm
 - History of thoughts or plan of self-harm in the past year in a person who is now extremely agitated, violent, distressed or uncommunicative





INITIAL (MEDICAL) EVALUATION



- Physical exam, emphasis on neuro
- History: travel, occupational exposure
- Urine drug screen
- Labs: ESR, ANA, TSH, Vitamin B12, Ceruloplasmin
 - HIV, FTA-ABS
- MRI if neuro exam abnormal



PSYCHOEDUCATION

- Recommend avoiding alcohol, cannabis or other nonprescription drugs.
- Advise on maintaining a healthy lifestyle.
- Encourage the person to resume social activities.
- Explain that symptoms can recur or worsen and the importance of visiting the health facility as soon as possible should this happen.
- Coordinate with available health and social resources to meet the family's physical, social, and mental health needs



STRESS REDUCTION







CHECKPOINT

Think about the last prescription you wrote for an antipsychotic medication...

- What was the indication for the medication you selected?
- Is the patient part of a population that is at increased risk from antipsychotic medications?
- What did you do to monitor the treatment?



SELECTING AN ANTIPSYCHOTIC MEDICATION



- First episode (antipsychotic naïve)
- Pregnancy
- Age
 - Elderly
 - Pediatric
- Concerns about side effects (weight gain, motor)
- Cost
- Patient preferences





| Indication | Age | Medications |
|-----------------------------------|--------|---|
| Schizophrenia, acute | Adults | ARI, ASE, BRE, CAR, ILO, LUR, OLZ, PAL, QUE, RIS, ZIP |
| Schizophrenia, maintenance | 13-17 | ARI, ASE, BRE ILO, OLZ, PAL, QUE, RIS, ZIP |
| Schizoaffective | Adults | PAL |
| Treatment-resistant schizophrenia | Adults | CLZ |
| Reduce suicide in schizophrenia | Adults | CLZ |
| Bipolar disorder | Adults | ARI, ASE, ILO, OLZ, QUE, RIS, ZIP |
| Bipolar disorder | 13-17 | ILO, OLZ (10-17: ARI, QUE, RIS) |
| Bipolar depression | Adults | LUR, QUE |
| Treatment-resistant depression | Adults | OLZ |
| Adjunctive MDD | Adults | ARI, BRE, QUE |
| Irritability in autism | 6-17 | ARI, RIS |



FIRST-LINE TREATMENT FOR EARLY PSYCHOSIS

- Risperidone (Risperdal) 3-4 mg (max 8 mg)
- Aripiprazole (Abilify) 10-30 mg (max 30 mg)
- Ziprasidone (Geodon) 80-120 mg (max 160 mg)




https://www.ontrackny.org



ANTIPSYCHOTIC MEDICATIONS IN CHILDREN

Figure 1. FDA-Approved Pediatric Age Ranges and Indications for Atypical Antipsychotics



^{*}Risperidone should not be used by patients older than age 16 who have been diagnosed with irritability with autistic disorder.

AP MEDICATION MANAGEMENT IN ELDERLY

 Increased mortality among elderly with dementia

| Medication | Schizophrenia |
|--------------|---------------|
| Aripiprazole | 15-30 mg |
| Clozapine | 50-150 mg |
| Olanzapine | 10-20 mg |
| Paliperidone | 3-12 mg |
| Quetiapine | 200-300 mg |
| Risperidone | 2-3 mg |

APA practice guidelines

https://psychiatryonline.org/doi/pdf/10.1176/appi.books.9780890426807



MEDICATION USE DURING PREGNANCY



- 1.3% of pregnancies exposed to AP meds
- Quetiapine and aripiprazole most prescribed
- Discontinuation: 53% increased risk of relapse (compared to 16%)
- Low reproductive risk
- Gestational diabetes RR = 1.28
- Breastfeeding not contraindicated (CLZ?)



WHAT ABOUT LAI?

Benefits

- Reduce relapse (5% vs 33%)
- Reduce hospitalizations
- Reduce mortality?
- Factors to consider
 - Patient preference
 - Tolerability
 - Individualized risk (of relapse)
 - Level of support





LAI: WHICH?

| Aripiprazole (Maintena) | 400 mg once a month |
|--------------------------------|--------------------------------|
| Aripiprazole (Aristada) | 441-882 monthly; 882 mg q 6wks |
| Olanzapine (Zyprexa Relprevv) | 150-300 mg q 2 w; 300-405 q m |
| Paliperidone (Invega Sustenna) | 39-117 mg once monthly |
| Paliperidone (Invega Trinza) | 410 mg q 3 months (273-819 mg) |
| Risperidone (Consta) | 25-50 mg q 2 weeks |



| Problem | Are you experiencing this problem? | | Questions for your psychiatrist |
|-----------------------------------|------------------------------------|----|---------------------------------|
| | Yes | No | |
| Daytime | | | |
| sedation/drowsiness/sleeping | | | |
| too much | | | |
| Problems with memory or | | | |
| concentration | | | |
| Changes in appetite or weight | | | |
| Muscles being too tense or | | | |
| stiff, or muscles trembling or | | | |
| shaking | | | |
| Feeling restless, jittery, or the | | | |
| need to move around and pace | | | |
| Blurry vision, dry mouth, | | | |
| constipation, or urinary | | | |
| retention or hesitancy | | | |
| Changes in sexual function | | | |
| [In women only], menstrual or | | | |
| breast problems | | | |
| Feeling unlike my usual self | | | |
| Other concerns | | | |
| | Yes | No | Questions for your Psychiatrist |
| I think the pros of using | | | |
| medication outweigh the cons | | | |
| of using medication | | | |



WHAT IS TARDIVE DYSKINESIA (TD)?

TARDIVE DYSKINESIA (TD)

is a condition characterized by uncontrollable, abnormal and repetitive movements of the trunk, extremities and/or face.^{1,2}


- Associated with the use of a dopamine receptor blocking agent (DRBA) for 3 or more months
- Regions affected: generally the tongue, lower face and jaw, and extremities

Risk factors

- Duration of exposure to AP Med
- Higher potency medication
- Age 50 +
- Post-menopausal
- Diagnosed with mood disorder
- History of drug or alcohol use disorder



ALL PATIENTS ON ANTIPSYCHOTICS ARE AT RISK OF DEVELOPING TD





IDENTIFYING TD

Look for movements throughout the body

- Orofacial movements
- Neck and trunk movements
- Arm and leg movements

Observation for involuntary movements

- In the waiting room
- Walking to the consultation room
- During the visit

If TD is suspected, perform a more thorough evaluation

- Observe ("look, not listen")
- Activation maneuvers
- AIMS



AIMS IS STANDARD STRUCTURED EXAM TO ASSESS TD

| | Movement Ratings | | | Sco | re | |
|---------------------|---|----|---|-----|----|---|
| | 1. Muscles of facial expression | 0 | 1 | 2 | 3 | 4 |
| Facial and Oral | 2. Lips and perioral area | 0 | 1 | 2 | 3 | 4 |
| Movements | 3. Jaw | 0 | 1 | 2 | 3 | 4 |
| | 4. Tongue | 0 | 1 | 2 | 3 | 4 |
| Extremity | 5. Upper (arms, wrists, hands, fingers) | 0 | 1 | 2 | 3 | 4 |
| Movements | 6. Lower (legs, knees, ankles, toes) | 0 | 1 | 2 | 3 | 4 |
| Trunk Movements | 7. Neck, shoulders, hips | 0 | 1 | 2 | 3 | 4 |
| | 8. Severity of abnormal movements overall | 0 | 1 | 2 | 3 | 4 |
| Global Judgments | 9. Incapacitation due to abnormal movements | 0 | 1 | 2 | 3 | 4 |
| Juuginents | 10. Patient awareness of abnormal movements | 0 | 1 | 2 | 3 | 4 |
| Dontal Status | 11. Current problems with teeth/dentures? | No | | Ye | S | |
| Dental Status | 12. Are dentures usually worn? | No | | Ye | S | |

Scoring

 Total score is calculated using items 1-7 for a total (max) score of 28

> 0 = None 1 = Minimal 2 = Mild 3 = Moderate 4 = Severe

 Item 8 score is based on the highest single score in any of the items 1-7




TD TREATMENT CONSIDERATIONS


- Minimize the use of anticholinergics (eg, benztropine), which can aggravate TD symptoms
- Dose reduction or discontinuation may not be feasible when the antipsychotic has already been optimized to improve mental health
- Reducing antipsychotic dose increases TD symptoms in the short term and may not improve TD symptoms in the long term
- TD may be irreversible, even upon antipsychotic discontinuation
- TD symptoms that have an impact on the patient, regardless of movement severity, should be managed first line with VMAT2 inhibitor




MECHANISM OF ACTION: VMAT2 INHIBITION



- VMAT2 is a transporter protein found in presynaptic neurons of the CNS
- VMAT2 packages monoamines (including dopamine) for release into the synaptic cleft







VESICULAR MONOAMINE TRANSPORTER 2 (VMT2) INHIBITORS

- FDA Approved medications
 - Tetrabenazine
 - Deutetrabenazine (Austedo)
 - 6 mg once daily, increase by 6 mg/day weekly; two divided doses; max dose 48 mg/d
 - Valbenazine (Ingrezza)
 - 40 mg once daily, increase to 80 mg once daily or continue 40-60 mg daily
- Side effects (similar effectiveness and tolerability)
 - Somnolence, diarrhea, dry mouth, HA, dizziness
 - QT prolongation



VESICULAR MONOAMINE TRANSPORTER 2 (VMT2) INHIBITORS

- Expensive
- Specialists/ Specialty pharmacy
- Duration of treatment? 12-week trials. Symptoms tend to recur when medication is stopped
- Alternatives
 - Discontinue any anticholinergic medications
 - OLZ, ILO, QUE, CLZ have lower risk of TD
 - Vitamin E, amantadine, clonazepam



Metabolic Monitoring Guidelines

ADA-APA workgroup. Diabetes Care 2004; 27: 596-601.

| | entry | 4 weeks | 8 weeks | 12 weeks | monthly | annual |
|----------------------|-------|------------|------------|-------------|---------|--------|
| PMH / Family History | X | | | | | X |
| Weight (BMI) | X | X | X | X | X | |
| Waist Circumference | X | | | | | X |
| Blood Pressure | X | X | X | X | X | X |
| Hemoglobin A1c | X | | | X | | X |
| Lipid panel | X | | | X | | X |
| Smoking Status | X | X | X | X | X | X |
| Physical activity | X | X | X | X | X | X |



SECOND GENERATION: METABOLIC RISKS

| Low Risk | Moderate Risk | High Risk |
|-------------------------|-------------------------|----------------------|
| Aripiprazole (Abilify) | Asenapine (Saphris) | Clozapine (Clozaril) |
| Brexpiprazole (Rexulti) | lloperidone (Fanapt) | Olanzapine (Zyprexa) |
| Cariprazine (Vraylar) | Paliperidone (Invega) | |
| Lumateperone (Caplyta) | Quetiapine (Seroquel) | |
| Lurasidone (Latuda) | Risperidone (Risperdal) | |
| Ziprasidone (Geodon) | | |

Barton BB et al Expert Opin Drug Saf. 2020 Mar;19(3):295-314. Corponi F et al Eur Neuropsychopharmacol. 2019 Sep;29(9):971-985.



WHEN SWITCH MEDICATIONS?



- Intolerable side effects
 - weight gain = 5-7% of bodyweight
 - Any magnitude of weight gain that leads to non-adherence with medication
 - New diagnosis of diabetes




HOW SWITCH?



- **Options**
 - Abrupt discontinuation and immediate initiation of second medication at clinically effective dose
 - Cross-taper (reduce 25-5-% every 4-5 days) with gradual initiation of new antipsychotic
 - Overlap and discontinuation: continue pre-switch med at full dose while starting and titrating new med
- No one strategy uniformly superior





AVOID POLYPHARMACY

- Meta-analysis of 147 studies
- 19.6% receive APP
- Rate increased 34% between 1980s and 2000s in North America
- APP associated with increased
 - hospitalization rates and length of stay
 - Costs
 - adverse effects, including mortality
- Augmentation of clozapine may be the exception





Choosing Wisely

https://www.choosingwisely.org

An initiative of the ABIM Foundation

| 1 | Don't routinely prescribe antipsychotic medications as a first-line intervention for insomnia in adults. |
|---|---|
| 2 | Don't routinely use antipsychotics as first choice to treat behavioral symptoms of dementia. |
| 3 | Don't routinely prescribe to treat behavioral symptoms of childhood mental disorders in the absence of approved or evidence supported indications |
| 4 | Don't routinely prescribe two or more antipsychotic medications concurrently |
| 5 | Don't prescribe antipsychotic medications for any indication without initial evaluation and ongoing monitoring. 38 02023 Linusesity of Washington |

CONCLUSIONS

- More than 1/3 of AP meds are prescribed by PCPs. Support improved care by
 - Clarifying indication, avoiding polypharmacy, recognizing special population
- Given superiority of LAI, these medications should be considered earlier. Guide to support shared decision making
- Choose Wisely. Tools are available to support monitoring

